RxDoctor Payments Data

Kenneth Gorney

Physician Assistant · Jackson, MINPI 1255380796

Payments from drug & device makers

$2,407in general payments, 2019–2025

Across 113 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Otsuka America Pharmaceutical, Inc.$269
  • Alkermes, Inc.$258
  • Teva Pharmaceuticals USA, Inc.$217
  • Idorsia Pharmaceuticals US Inc$117
  • Indivior Inc.$115
  • plus $395 from 8 others

What the payments were for

  • Food & beverage$2,25594%
  • Education$1526%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,407 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$32,421
Medicare patients
50
Services billed
393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole12$28,623
CaplytaLumateperone Tosylate16$25,229
TrintellixVortioxetine Hydrobromide12$9,203
Duloxetine Hcl124$5,262
Fluphenazine Hcl15$1,814
Memantine Hcl ErMemantine Hcl11$1,719
Mirtazapine100$1,446
Divalproex Sodium16$1,010
Citalopram HbrCitalopram Hydrobromide39$953
Trazodone Hcl140$883
Bupropion XlBupropion Hcl61$880
Buspirone Hcl96$851
Olanzapine53$841
Clonazepam133$795
Quetiapine Fumarate ErQuetiapine Fumarate25$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$269$28,62312 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,037$25,22916 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$9,20312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Jackson

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →